Clinical trials
Induction Chemotherapy clinical trials
Below are recruiting induction chemotherapy clinical trials, each written for real people, not researchers. We’re tracking 73 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT07370337RecruitingPhase 2
Chemotherapy plus immunotherapy for ear canal cancer
This trial tests combining chemotherapy with the immunotherapy drug tislelizumab for advanced squamous cell carcinoma of the ear canal. It may help shrink tumors that haven't spread to other parts of the body.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07496190RecruitingPhase 2
Becotatug Vedotin for advanced nasopharyngeal cancer not responding well to initial treatment
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
Guangzhou, GuangdongAges 18–70 - NCT07706985RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT03326947RecruitingPhase 2
Stathmin test to guide chemotherapy for oral cancer
This Phase 2 trial uses a lab test called “Stathmin” to help predict who may benefit from a specific chemotherapy plan for squamous cell carcinoma of the mouth. It aims to improve treatment choice by linking Stathmin levels to how well chemotherapy works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03439371Recruiting
Micro-transplant treatment for older adults with AML in remission
This trial studies a gentler (“micro-”) transplant approach for people ages 60–74 with acute myeloid leukemia (AML) who are in remission and cannot safely have the usual stronger transplant conditioning. It may help reduce transplant risks while keeping the leukemia under control.
Clermont-FerrandAges 60–75 - NCT03534713RecruitingPhase 3
Cervical cancer treatment plan after lymph node spread
This trial tests a specific chemotherapy start (induction) followed by standard treatment for cervical cancer that has spread to lymph nodes near the aorta. It may help improve cancer control compared with standard timing/approach.
BordeauxAges 18 years+ - NCT04389086RecruitingPhase 3
Chemotherapy before surgery for recurring rectal cancer
This trial tests an “induction chemotherapy” treatment before surgery for people whose rectal cancer has come back in the local area. The goal is to shrink/control the cancer early and improve outcomes after treatment.
GhentAges 18 years+ - NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+ - NCT05173272RecruitingPhase 3
Immunotherapy plus chemo, then radiation, for advanced cervical cancer
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
Chengdu, SichuanAges 18 years+ - NCT05272696RecruitingPhase 2
Pembrolizumab plus chemo before treatment for advanced head and neck cancer
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Guangzhou, GuangdongAges 18–70 - NCT05508347RecruitingPhase 2
Testing a new antibody with chemo for locally advanced throat cancer
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
Chengdu, SichuanAges 18–70 - NCT05527470RecruitingPhase 3
Chemo then radiation for newly diagnosed advanced nasopharyngeal cancer
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
Guilin, GuangxiAges 18–65 - NCT05628922RecruitingPhase 2
Blood EBV DNA–guided therapy for advanced nasopharyngeal cancer
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05717790Recruiting
Nimotuzumab with chemo and radiation for advanced nose cancer
This trial tests whether adding nimotuzumab (an anti-EGFR antibody) to standard chemotherapy and radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. It may help the cancer respond better and control it more effectively after treatment.
Baise City, GuangxiAges 18–70 - NCT05777824RecruitingPhase 2
Testing treatment after head and neck cancer response to chemo-immunotherapy
This Phase 2 study looks at what treatment is best after you first receive chemotherapy plus immunotherapy, then have surgery for head and neck squamous cell cancer. It tries to use how your tumor responds (shown in lab tissue after treatment) to guide the next steps, which may improve outcomes.
Beijin, Beijing MunicipalityAges 18–75 - NCT05877872RecruitingPhase 3
Smaller surgery after chemotherapy for recurring nasopharyngeal cancer
This trial tests whether doing a smaller surgery (after chemotherapy works well) can control recurring nasopharyngeal cancer while reducing treatment burden. It is for people whose cancer can be removed by surgery and who respond to an initial course of chemotherapy plus immunotherapy (or another targeted regimen).
Guangzhou, GuangdongAges 18–75 - NCT05907057RecruitingPhase 3
Ivosidenib plus azacitidine for newly diagnosed AML
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
ViennaAges 18 years+ - NCT05914389RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for colon cancer
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
Hangzhou, ZhejiangAges 18–75 - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06255210RecruitingPhase 2
Chemotherapy before surgery for olfactory neuroblastoma
This trial tests whether giving chemotherapy before surgery can help treat olfactory neuroblastoma, a rare type of nose cancer. It aims to see how safe and effective this approach is for people with early to advanced tumors that have not spread to other parts of the body.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70
Hear when a new Induction Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for induction chemotherapy?
- Yes. Clin2 currently lists 73 recruiting induction chemotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a induction chemotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a induction chemotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.